Analyst Ratings for Bristol-Myers Squibb Co. (bmy)
bmy Rating Summary
bmy Price Target Summary
- Highest: $82.00 (Piper Sandler)
- Lowest: $41.00 (Morgan Stanley)
- Average: $65.75
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$65.75 (+11.2%)
* Over Last 12-Mos
Rating Score: 2.9 / 10
Percentile Rank: 24%
Avg. $ Target:
$65.75 (+11.2%)
* Over Last 12-Mos
Rating Score: 2.9 / 10
Percentile Rank: 24%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/5/2026 | Leerink | David Risinger | Downgrade | Market Perform (Outperform) |
59.00 (N/A) |
61.15 (59.12) |
-3.32% | Details |
| 8/5/2026 | Argus | Jasper | Upgrade | Buy (Hold) |
75.00 (N/A) |
65.89 (59.12) |
-10.27% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
